Showing 5961-5970 of 9397 results for "".
- Cutanea Life Sciences Unveils Facing Forward Mobile App for Acne Patientshttps://practicaldermatology.com/news/cutanea-life-sciences-unveils-facing-forward-new-mobile-app-for-acne-patients/2458104/Cutanea Life Sciences, Inc. introduced its Facing Forward mobile application for patients who are prescribed Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The app will be available free thro
- MKTP Surgery Shows Long-Term Benefit for Restoring Skin Pigmentation in Vitiligohttps://practicaldermatology.com/news/mktp-surgery-shows-long-term-benefit-for-restoring-skin-pigmentation-in-vitiligo/2458103/Melanocyte-keratinocyte transplantation (MKTP) provides long-term benefits for restoring skin pigmentation caused by vitiligo, report researchers from Henry Ford Hospital in Detroit. “MKTP works and it lasts a long time,” says Iltefat Hamzavi, M.D., a Henry Ford dermatologist
- Valeant Launches Siliq Injection for Psoriasishttps://practicaldermatology.com/news/valeant-launches-siliq-injection-for-psoriasis/2458107/Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. Siliq, a
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Joseph H. Boccuzi Appointed to Allergan plc Board of Directorshttps://practicaldermatology.com/news/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors/2458116/Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma